Neutralizing Monoclonal Antibody Sars-Cov

SARS-CoV-2 Spike Monoclonal Antibody
A73664
  • EUR 341.00
  • EUR 518.10
  • 50 ul
  • 100 ul

Human IgG antibody Laboratories manufactures the neutralizing monoclonal antibody sars-cov reagents distributed by Genprice. The Neutralizing Monoclonal Antibody Sars-Cov reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact SARS Monoclonal. Other Neutralizing products are available in stock. Specificity: Neutralizing Category: Monoclonal Group: Antibody Sars-Cov

SARS-CoV Spike Antibody
0.02 mg
EUR 206.18
Description: SARS-CoV Spike Antibody: A novel coronavirus has been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.

SARS-CoV Spike Antibody
0.1 mg
EUR 523.7
Description: SARS-CoV Spike Antibody: A novel coronavirus has been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.

SARS-CoV Spike Antibody
0.02 mg
EUR 206.18
Description: SARS-CoV Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.

SARS-CoV Spike Antibody
0.1 mg
EUR 523.7
Description: SARS-CoV Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.

SARS-CoV Spike Antibody
0.02 mg
EUR 206.18
Description: SARS Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.

SARS-CoV Spike Antibody
0.1 mg
EUR 523.7
Description: SARS Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.

SARS-CoV Spike Antibody
0.02 mg
EUR 206.18
Description: SARS-CoV Spike antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.

Antibody Sars-Cov information

Mouse monoclona Anti-Rabies Virus Glycoprotein (RVG) IgG, neutralizing (clone 1)
RBVGP12-M 100 ul
EUR 578.4

Mouse monoclona Anti-Rabies Virus Glycoprotein (RVG) IgG, neutralizing (clone 2)
RBVGP13-M 100 ul
EUR 578.4

Cytomegalovirus gB Late Neutralizing Antigen (CMV-LA gB Neutralizing) Antibody (FITC)
abx411284-01mg 0.1 mg
EUR 610.8

Anti-BTLA Neutralizing Antibody
100244 100 µg
EUR 355
Description: This anti-BTLA antibody is a purified recombinant human monoclonal antibody which recognizes the human BTLA protein. BTLA (B- and T-lymphocyte attenuator) belongs to the CD28 immunoglobulin superfamily (IgSF) and is an immune-regulatory receptor that binds to HVEM (Herpesvirus entry mediator, also known as TNFRSF14, Tumor necrosis factor receptor superfamily member 14). This antibody has been tested for specific binding to purified human BTLA protein and neutralizes the interaction between BTLA and HVEM.

Anti-VEGF Neutralizing Antibody
79478-1 50 µg
EUR 355
Description: Anti-VEGF recombinant Human antibody. This antibody not been tested for cross-reactivity with other species.

Anti-VEGF Neutralizing Antibody
79478-2 100 g
EUR 460
Description: Anti-VEGF recombinant Human antibody. This antibody not been tested for cross-reactivity with other species.

Anti-LAG3, Neutralizing Antibody
71219 100 µg
EUR 530
Description: Neutralizing recombinant human antibody recognizing the Lag-3 binding region.

Human Monoclonal Anti-Dengue Virus Type 1-4 Envelop protein Domiam III (Env-DIII) IgG1 (reacts with DV1-4 DIIII, neutralizing)
DV1234E22-M 100 ul
EUR 578.4

Anti-VISTA Neutralizing Antibody
101293 100 µg
EUR 450
Description: This human monoclonal antibody recognizes human V-domain immunoglobulin (Ig) suppressor of T cell activation (VISTA), and neutralizes its interaction with VSIG3 (also called IGSF11). VISTA is also known as B7-H5 or VSIR (GenBank Accession No. NM_022153). VSIG3 is a ligand involved in cell adhesion as a VISTA binding partner. This neutralizing antibody has been functionally tested using the VSIG-3:VISTA [Biotinylated] Inhibitor Screening Assay Kit (BPS Bioscience #79782).

Anti-RANKL Neutralizing Antibody
100874-1 50 µg
EUR 335
Description: Human, recombinant monoclonal antibody recognizing the RANKL protein, also known as TNFSF11 antibody and CD254 antibody. This antibody recognizes human RANKL. It has not been tested with other species. MW= 50 kDa (Heavy chain); 24 kDa (Light chain).

Anti-RANKL Neutralizing Antibody
100874-2 100 µg
EUR 460
Description: Human, recombinant monoclonal antibody recognizing the RANKL protein, also known as TNFSF11 antibody and CD254 antibody. This antibody recognizes human RANKL. It has not been tested with other species. MW= 50 kDa (Heavy chain); 24 kDa (Light chain).

Anti-PCSK9 Neutralizing Antibody
71207 50 µg
EUR 555
Description: Neutralizing recombinant human antibody (IgG1) recognizing the LDLR binding region of human PCSK9.

Anti-TIGIT Neutralizing Antibody
71340 100 µg
EUR 565
Description: Human Anti-TIGIT neutralizing antibody recognizing the TIGIT binding region on immune cells.

Mouse Monoclonal Anti-Zika Virus Envelope Protein DIII (EDIII) IgG (non-reactive with related flavivruses; Neutralizing)
ZENV15-M 100 ul
EUR 578.4

Human Monoclonal Anti-Dengue Virus Type 1-4 Envelop protein Domiam I-II (Env-DI-II) IgG1 (reacts with DV1-4 DIIII, neutralizing)
DV1234E23-M 100 ul
EUR 578.4

Anti-PD-1 Neutralizing Antibody
71120 100 µg
EUR 465
Description: Neutralizing recombinant murine/human chimeric antibody recognizing the PD-L1/PD-L2 binding region of human PD-1. This antibody does not cross-react with mouse PD-1, but does cross-react with monkey (M. fascicularis) PD-1. It has not been tested with other species.

Humanized Monoclonal Anti-Zika Virus Envelope Protein DIII (EDIII) IgM (non-reactive with related flavivruses; Neutralizing)
ZENV16-M 100 ul
EUR 578.4